160
Participants
Start Date
January 1, 2023
Primary Completion Date
September 1, 2024
Study Completion Date
September 30, 2024
Silymarin
Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
Institute of Cardiovascular Diseases of Vojvodina, Kamenitz
University of Novi Sad
OTHER